HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.

ABSTRACT:

Background

The presence of CAR in diverse tumor types is heterogeneous with implications in tumor transduction efficiency in the context of adenoviral mediated cancer gene therapy. Preliminary studies suggest that CAR transcriptional regulation is modulated through histone acetylation and not through promoter methylation. Furthermore, it has been documented that the pharmacological induction of CAR using histone deacetylase inhibitor (iHDAC) compounds is a viable strategy to enhance adenoviral mediated gene delivery to cancer cells in vitro. The incorporation of HDAC drugs into the overall scheme in adenoviral based cancer gene therapy clinical trials seems rational. However, reports using compounds with iHDAC properties utilized routinely in the clinic are pending. Valproic acid,

SUBMITTER: Segura-Pacheco B 

PROVIDER: S-EPMC2174455 | biostudies-literature | 2007 Sep

REPOSITORIES: biostudies-literature